Eli Lilly is delivering exceptional growth from Mounjaro and Zepbound, but the stock already reflects a premium multiple and heavy concentration in its obesity franchise.
Eli Lilly (LLY) has become one of the fastest-growing large pharmaceutical companies, with Q3 2026 revenue of $24.4B, up 39% year over year, and non-GAAP EPS of $7.48, up 7%. Management raised 2026 revenue guidance to $91B-$92B and expects non-GAAP EPS of $35-$36. The core investment case rests on the continued expansion of Mounjaro, Zepbound, and the next generation of oral and triple-agonist treatments.
The growth engine is unusually powerful. Mounjaro and Zepbound generated more than $16B in combined Q3 revenue, while U.S. obesity prescriptions grew 82% and international incretin sales rose 53% year over year. Foundayo adds an oral obesity product, retatrutide extends the pipeline into a higher-efficacy triple agonist, and newer oncology, immunology, and neuroscience products provide a second layer of growth.
The counterweight is valuation and concentration. LLY trades at 43.3 times trailing earnings and 27.0 times forward earnings, while Mounjaro and Zepbound represented 56% of 2025 revenue. U.S. realized price declined 10% excluding a favorable rebate adjustment, and debt rose to $54.9B by June 2026. For a moderate-risk investor, the result is a Buy recommendation rather than an aggressive chase: the business earns a premium, but the share price already assumes strong execution.
Eli Lilly is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis. It employs approximately 50,000 people and sells medicines in the United States, Europe, China, Japan, and other international markets. Its portfolio covers cardiometabolic health, oncology, immunology, neuroscience, migraine, and diabetes.
The business is shifting from a diversified pharmaceutical model toward a cardiometabolic-led model. Product revenue reached $61.0B in 2025, or 93.5% of total revenue, while collaboration and other revenue contributed $4.2B, or 6.5%. Total 2025 revenue was $65.2B, compared with $45.0B in 2024 and $34.1B in 2023.
Lilly is also building a direct access layer through LillyDirect and is using cash flow from its established products to fund manufacturing, research, acquisitions, and shareholder returns. The company paid $1.5B in dividends and repurchased $400M of stock in Q3 2026.
Lilly reports revenue mainly through products and collaboration activity rather than a detailed operating-segment structure. Cardiometabolic health is the dominant economic segment. Mounjaro produced $10.7B of Q3 2026 revenue, up 65% year over year, and Zepbound produced $5.4B, up 49%.
The newer franchises are growing from smaller bases but are becoming meaningful. Ebglyss revenue rose 59% to $202M, Jaypirca revenue rose 59% to $228M, and Kisunla revenue rose 175% to $193M. Foundayo generated $184M in its launch quarter, while Inluriyo generated $73M.
Geographic breadth is another positive. U.S. revenue grew 34% in Q3, revenue outside the U.S. grew 47%, China revenue grew 62% in constant currency, and the rest of the world grew 87% in constant currency. The mix is still U.S.-heavy, but international Mounjaro demand is expanding the commercial runway.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Mounjaro and Zepbound are the center of the LLY thesis. Mounjaro treats type 2 diabetes, while Zepbound serves obesity. In the U.S., Lilly held more than 60% of the type 2 diabetes incretin market and more than 70% of injectable obesity prescriptions in Q3 2026.
The products are gaining both volume and access. Total U.S. incretin prescriptions grew 32% year over year, and more than half a million people filled a Lilly prescription through the Medicare GLP-1 bridge program after its July 1 launch. Seven of every 10 new bridge patients started on a Lilly obesity medicine.
The commercial challenge is price. U.S. revenue grew 34%, but reported price declined 7%, or 10% excluding a favorable rebate and discount adjustment. That tradeoff shows the basic pharmaceutical equation clearly: Lilly is accepting lower realized pricing to widen access and drive much higher volume.
Management's statement is supported by current penetration data. Lilly said it reaches roughly 1 in 10 relevant U.S. patients and 2 in 100 patients outside the U.S. The opportunity is substantial, although the eventual return to shareholders will depend on reimbursement, supply, pricing, and competitive efficacy.
Lilly's strongest advantage is the combination of clinical efficacy, commercial execution, and a stacked incretin pipeline. Retatrutide reduced A1C by 2.2% versus 1.8% for 2 milligrams of semaglutide in a head-to-head type 2 diabetes trial. It also produced 20%-21% weight loss versus 9.4% for the semaglutide group.
Foundayo gives Lilly an oral entry point. Approximately 4 in 10 patients starting an oral obesity medicine chose Foundayo in Q3, and new Foundayo patients doubled from the prior quarter. Orforglipron also met the primary cardiovascular safety endpoint in ACHIEVE-4 and showed a 16% lower risk of major adverse cardiovascular events versus insulin glargine in a prespecified analysis.
The innovation platform extends beyond obesity. Lilly has eight oncology medicines or major indications in Phase 3 trials or approaching Phase 3, while three-fourths of its clinical pipeline focuses on diseases outside obesity. Acquisitions of AtaiBeckley and Merida Biosciences add neuroscience and precision immunology programs.
Manufacturing capacity is a strategic asset because obesity demand has grown faster than conventional pharmaceutical supply systems. Lilly broke ground on a $6.5B facility in Houston and a $5B facility in Richmond, Virginia. The projects add to more than $21B of Indiana capital expansion commitments since 2020.
Capital spending is already significant. Lilly spent $7.8B on capital expenditures in 2025, compared with $5.1B in 2024 and $7.4B in 2023. That investment reduced 2025 free cash flow to $9.0B despite operating cash flow of $16.8B, but it also supports future product launches and reduces the risk that supply becomes the main limit on revenue.
The operating model combines manufacturing with access infrastructure. LillyDirect gives the company a direct patient engagement channel, while the Medicare bridge program and expanded PBM coverage reduce payment friction. The cost is higher commercial spending, with marketing, selling, and administrative expense up 14% in Q3 and research and development expense up 23%.
The global pharmaceutical market was estimated at $1.9T in 2026 and is projected to reach $2.6T by 2031 at a 6.7% compound annual growth rate. Lilly is growing far faster than that broad market because it is concentrated in obesity, diabetes, specialty medicines, and other categories with above-market demand.
Lilly's own materials place current penetration at roughly 5% of the addressable 2030 obesity and diabetes market. That provides a measurable runway for new patient starts, broader reimbursement, international expansion, and oral formulations.
The market is also shifting toward biologics, specialty therapies, and digital fulfillment. Biologics and biosimilars were projected to grow at an 8.2% rate through 2031, while online pharmacies were projected to grow at 8.1%. Lilly's injectable and oral incretin products fit both trends, although patent protection and payer negotiations remain central to profitability.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Lilly serves patients with chronic metabolic, immune, cancer, neurological, and migraine conditions. The most important customer group is now adults with type 2 diabetes or obesity who need long-duration treatment. The Medicare bridge program covers approximately 20 million U.S. seniors, making older adults an increasingly important demand pool.
The customer decision is shaped by efficacy, tolerability, convenience, physician prescribing, and reimbursement. Zepbound's persistence in covered and self-pay markets was described by management as comparable to Trulicity's 16-18 month chronic-treatment adherence pattern. Weekly injections offer a convenience advantage over daily treatment, while Foundayo addresses patients who prefer an oral product.
Payers and pharmacy benefit managers are also customers in economic terms. Coverage from the three largest U.S. PBMs for Lilly's obesity portfolio expands access, but the 10% U.S. price decline excluding the rebate adjustment shows how payer leverage can affect reported revenue per patient.
Novo Nordisk is Lilly's most direct competitor in obesity and diabetes through Ozempic, Wegovy, and Rybelsus. The principal contest is moving from injectable efficacy toward access, manufacturing scale, oral convenience, cardiovascular outcomes, and treatment persistence.
Lilly's current advantage is commercial share and pipeline breadth. Mounjaro held more than 60% of the U.S. type 2 diabetes incretin market, while Lilly reached approximately 58% share of international incretins after gaining nearly 4 percentage points from Q2 2026. Foundayo and retatrutide give Lilly additional products in development rather than leaving the company dependent on one formulation.
Outside cardiometabolic health, Lilly competes with Merck, Roche, Bristol Myers Squibb, AstraZeneca, AbbVie, Johnson & Johnson, Biogen, and others. Jaypirca, Ebglyss, Inluriyo, and Kisunla are growing quickly, but each remains much smaller than Mounjaro or Zepbound. The diversification effort is progressing, not complete.
Healthcare policy is directly affecting Lilly's revenue path. The Medicare GLP-1 bridge program added access for approximately 20 million seniors, and more than 500,000 people filled a Lilly prescription through the program after launch. A University of Southern California estimate placed potential Medicare savings from broader anti-obesity coverage above $20B over 10 years, strengthening the economic case for coverage.
Pricing policy remains a material offset. U.S. revenue grew 34% in Q3 while price declined 7%, and the decline was 10% after removing a favorable rebate adjustment. Lilly's 2027 outlook also includes net realized price as a headwind, with volume expected to offset it.
Geographic exposure creates both growth and execution risk. China revenue grew 62% in constant currency, Japan grew 26%, and the rest of the world grew 87%, but international sales expose Lilly to currency movement, local reimbursement systems, import rules, and regulatory differences. The Houston and Richmond facilities also show that domestic manufacturing has become a strategic response to capacity and supply-chain requirements.
Debt rose to $54.9B by June 2026, but Lilly is still funding manufacturing, R&D, acquisitions, dividends, and buybacks from powerful cash generation.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q3 2026 revenue jumped 39% to $24.4B while non-GAAP EPS rose 7% to $7.48, showing growth that is still outpacing earnings dilution from pricing pressure.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to $91B-$92B and expects non-GAAP EPS of $35-$36, signaling continued momentum from Mounjaro, Zepbound, and new launches.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →LLY trades at 43.3x trailing earnings and 27.0x forward earnings, with Mounjaro and Zepbound still accounting for 56% of 2025 revenue.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value sits at $1,337, below the $1,480 sell level and well under the $1,650 strong-sell threshold, reflecting a premium stock that still earns a Buy.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Eli Lilly has built one of the strongest growth platforms in global pharmaceuticals. Q3 revenue rose 39%, Mounjaro and Zepbound generated more than $16B in combined revenue, international incretin share reached approximately 58%, and management raised 2026 revenue guidance to $91B-$92B.
The investment is not risk-free. Mounjaro and Zepbound represented 56% of 2025 revenue, U.S. price declined 10% excluding a rebate adjustment, debt reached $54.9B by June 2026, and 2026 included approximately $2B of one-time benefits. Those facts make valuation discipline essential.
The medium-term balance still favors ownership over avoidance. Lilly's earnings growth, manufacturing expansion, oral obesity launch, retatrutide data, and expanding oncology, immunology, and neuroscience franchises support a Buy recommendation, with the strongest risk-adjusted entry below the latest quoted price and a $1,337 fair value estimate.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Eli Lilly and Company (LLY) rises after a strong Q3 earnings report topped revenue estimates and management lifted full-year guidance. Demand for Mounjaro and Zepbound powered the quarter, while investors also reacted to faster growth across newer pipeline and commercial products.
Eli Lilly delivered 48% Q2 revenue growth and raised full-year guidance, but the stock already prices in a lot of that momentum. Hold reflects strong execution, a deep pipeline, and a premium valuation that limits upside.
Eli Lilly and Company (LLY) rises after a strong earnings-driven repricing tied to its obesity franchise, Q2 beat, and higher 2026 guidance. The stock moved above its listed 52-week high as investors focused on Mounjaro, Zepbound, and continued growth momentum. Volume data does not confirm a breakout.